GenSight Biologics

Company snapshot

GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for GenSight Biologics. Not investment advice.

• What is GenSight Biologics?

  GenSight Biologics is a pharma organization headquartered in EU. Primary therapeutic focus areas include Retinitis Pigmentosa. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO

• Is GenSight Biologics publicly traded?

  GenSight Biologics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does GenSight Biologics develop or market?

  We link 2 drug profile(s) where GenSight Biologics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/gensight-biologics-s-a#company-drugs.

• What are the latest developments for GenSight Biologics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does GenSight Biologics focus on?

  GenSight Biologics focuses on Retinitis Pigmentosa based on our analysis of their pipeline programs and drug development activities.